Alexion's Wilson Therapeutics Deal Beats Its Synageva Distaster - Bloomberg
AstraZeneca dumps $855M, near-approval rare disease drug
Alexion adds to pipeline rebuild with $855m Wilson buy - PMLiVE
Alexion gets rare-disease-focused Wilson
Wilson Disease Association - Learn more about genetic testing and new treatments being developed for Wilson disease from this free webinar being held April 20th. Featured speaker Dr. Eve Roberts is on
Alexion Acquires Swedish Treatment for Wilson's Disease
ex995wtxofferstatement
Chantel Wilson Chase | SpeakerHub
ALEXION PHARMACEUTICALS, INC. - ALEXION'S NEXT CHAPTER Our Next Chapter & Advances shared mission of following the science and using innovative approaches to develop life-changing medicines for patientsStrengthens AstraZeneca's presence in immunology
Alexion's Wilson Therapeutics Deal Beats Its Synageva Distaster - Bloomberg
Drug Candidate for Wilson Disease Meets Primary Endpoint in Phase III Trial | BioSpace
Alexion Pharmaceuticals to acquire Wilson Therapeutics for $855mn
Alexion to Acquire Wilson Therapeutics for $855 Million - Equities News
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1) (NASDAQ:ALXN) | Seeking Alpha
Data backs AZ's Wilson disease drug, but with a question mark | pharmaphorum
UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ALEXION PHARMACEUTICALS, INC.
AstraZeneca celebrates copper-bottomed deal after Alexion purchase
Alexion Purchases Wilson Therapeutics for $855M: Expands Pipeline | BioSpace
Alexion Might Finally Satisfy The Market (NASDAQ:ALXN) | Seeking Alpha
Alexion to Acquire Wilson Therapeutics | Business Wire
Alexion in €639m bid for Wilson Therapeutics AB - European Biotechnology
ALXN1840 FoCus Phase III Trial in Wilson Disease Met Primary Endpoint Demonstrating Improvement in Copper Mobilisation from Tissues-CliniExpert
Alexion's drug meets primary goal in Phase III Wilson disease trial
